Aspirin Use May Improve Survival With Some Cancers
Investigators found no survival benefit among older patients with esophageal, gastric, pancreatic, or uterine cancer taking aspirin.
All articles by Natasha Persaud
Lower Risk of CKD Stage Progression Found With Apixaban
Kidney injury may be less among patients with chronic kidney disease and atrial fibrillation taking apixaban versus warfarin for anticoagulation, new research suggests.
Anticholinergics Linked to Increased Dementia Risk
Physicians should carefully weigh the risks against the potential benefits before prescribing anticholinergics, according to investigators.
No Increased Cardiovascular Risk With Febuxostat vs Allopurinol
In contrast to CARES, FAST found that treatment with febuxostat was not associated with an increase in cardiovascular or all-cause death compared with allopurinol in patients with gout.
OAB Drug May Improve Outcomes in Botulinum Toxin Recipients
Pharmacologic therapy may improve symptoms in patients with refractory overactive bladder who receive intravesical onabotulinum toxin-A injections.
Factors Contributing to Darbepoetin Responsiveness in CKD
In a Japanese study, approximately 1 in 8 CKD patients with anemia failed to respond to darbepoetin alfa therapy.
Eplerenone May Improve Albumin Excretion in T2D With Acceptable Safety
Research suggests the use of additional treatment options, such as the mineralocorticoid receptor antagonist eplerenone, might prevent or delay overt diabetic nephropathy.
Vadadustat Noninferior to Darbepoetin in CKD
Despite favorable efficacy data, the HIF-PHI failed to demonstrate noninferiority to the ESA in patients with CKD with respect to the primary MACE safety endpoint.
Dapagliflozin Reduces Hyperkalemia Risk in Heart Failure Treated With MRAs
Secondary results from the DAPA-HF trial suggest the sodium-glucose cotransporter 2 inhibitor may enable use of mineralocorticoid receptor antagonists in some patients with heart failure.
Empagliflozin Beneficial in Heart Failure With Reduced Ejection Fraction
In a trial, empagliflozin reduced the risks for heart failure hospitalization and renal outcomes in patients with heart failure with reduced ejection fraction.
